Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Ami V, Desai"'
Autor:
Mohansrinivas Chennakesavalu, Caileigh Pudela, Mark A. Applebaum, Sang Mee Lee, Yan Che, Arlene Naranjo, Julie R. Park, Samuel L. Volchenboum, Tara O. Henderson, Susan L. Cohn, Ami V. Desai
Publikováno v:
EJC Paediatric Oncology, Vol 2, Iss , Pp 100022- (2023)
Background: Racial/ethnic survival disparities in neuroblastoma were first reported more than a decade ago. We sought to investigate if these disparities have persisted with current era therapy. Methods: Two patient cohorts were identified in the Int
Externí odkaz:
https://doaj.org/article/0884887593ac4022bd8dab8a00e8d3e1
Autor:
Ami V Desai, Stefani Spranger, Thomas F Gajewski, Yuanyuan Zha, Jason J Luke, Peter Pytel, Kyle Hernandez, Samuel L Volchenboum, Susan L Cohn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background Tumor-infiltrating CD8+ T cells and neoantigens are predictors of a favorable prognosis and response to immunotherapy with checkpoint inhibitors in many types of adult cancer, but little is known about their role in pediatric malignancies.
Externí odkaz:
https://doaj.org/article/b260b4d6e43c4d658b87dc58bb5c263c
Autor:
Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G. Groshen, Judith G. Villablanca, Kateryna Krytska, Lillian M. Lai, Patricia T. Acharya, Fariba Goodarzian, Bruce Pawel, Hiroyuki Shimada, Susan Ghazarian, Lisa States, Lynley Marshall, Louis Chesler, Meaghan Granger, Ami V. Desai, Rajen Mody, Daniel A. Morgenstern, Suzanne Shusterman, Margaret E. Macy, Navin Pinto, Gudrun Schleiermacher, Kieuhoa Vo, Holger C. Thurm, Joseph Chen, Marlon Liyanage, Gerson Peltz, Katherine K. Matthay, Esther R. Berko, John M. Maris, Araz Marachelian, Yael P. Mossé
Publikováno v:
Nature Medicine. 29:1092-1102
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in childre
Autor:
Ami V. Desai, Andrew L. Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B. London, Sheena C. Tenney, Mitchell Diccianni, Jacquelyn A. Hank, Marguerite T. Parisi, Barry L. Shulkin, Malcolm Smith, Jeffrey A. Moscow, Hiroyuki Shimada, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Paul M. Sondel, Julie R. Park, Alice L. Yu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(35)
PURPOSEPostconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2 improved outcomes for patients with high-risk neuroblastoma enrolled on the randomized portion of Children's Oncology Gr
Autor:
Benjamin J. Lerman, Yimei Li, Cecilia Carlowicz, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Brian D. Weiss, Michelle Choe, Jennifer H. Foster, Navin Pinto, Daniel A. Morgenstern, Margarida Simão Rafael, Keri A. Streby, Rachel N. Zeno, Rajen Mody, Sahr Yazdani, Ami V. Desai, Margaret E. Macy, Suzanne Shusterman, Sara M. Federico, Rochelle Bagatell
Publikováno v:
Journal of Clinical Oncology. 41:508-516
PURPOSE Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macroph
Autor:
Hari K Narayan, Mary E Putt, Nikitha Kosaraju, Alejandro Paz, Shivani Bhatt, Theodore Plappert, Laura Mercer-Rosa, Saro H Armenian, Ami V Desai, Richard B Womer, Bonnie Ky
Publikováno v:
Open Heart, Vol 6, Iss 1 (2019)
Objective We sought to determine how sex and dexrazoxane therapy influence cardiac remodelling in children with sarcoma receiving high-dose doxorubicin.Methods In a retrospective cohort of 85 children with sarcoma receiving high-dose doxorubicin, ech
Externí odkaz:
https://doaj.org/article/8641b9de8fbe4f6f8281b34e39f8520a
Autor:
Ami V. Desai, Mark A. Applebaum, Theodore G. Karrison, Akosua Oppong, Cindy Yuan, Katherine R. Berg, Kyle MacQuarrie, Elizabeth Sokol, Anurekha G. Hall, Navin Pinto, Ian Wolfe, Rajen Mody, Suzanne Shusterman, Valeria Smith, Jennifer H. Foster, Michele Nassin, James L. LaBelle, Rochelle Bagatell, Susan L. Cohn
Publikováno v:
Cancer. 128:2967-2977
High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multi
Autor:
Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
Publikováno v:
Neuro-Oncology. 24:1776-1789
Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Purpose:CD137 agonism and CSF1R blockade augment stereotactic body radiotherapy (SBRT) and anti-programmed death-1 in preclinical models. We evaluated the safety and efficacy of SBRT with nivolumab+urelumab (CD137 agonist) or nivolumab+cabiralizumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6536beb4678e9cb73dd39e2e5832f0
https://doi.org/10.1158/1078-0432.c.6530619
https://doi.org/10.1158/1078-0432.c.6530619
Autor:
Jason J. Luke, Steven J. Chmura, Sean P. Pitroda, Ralph R. Weichselbaum, Mark D. Hoffman, Julia Dai, Linda A. Janisch, Robyn Hseu, Hedy L. Kindler, Everett E. Vokes, Peter H. O'Donnell, Olwen M. Hahn, Blase N. Polite, Rita Nanda, Mark J. Ratain, John W. Moroney, Ami V. Desai, Chih-Yi Liao, Theodore G. Karrison, Gini F. Fleming, Corey C. Foster
Table S1 shows the included solid tumor histologies for enrolled patients. Table S2 shows at least possibly treatment-related grade 2 or greater adverse events among patients remaining on study for at least 3 months. Table S3 shows all adverse events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89653394de468c7c4c7a3b5bd38dc711
https://doi.org/10.1158/1078-0432.22481121
https://doi.org/10.1158/1078-0432.22481121